Please assess the completion status of the following clinical trial:

Trial Title: Open-label Follow-up Trial of Fixed Dose Combination of Telmisartan + Hydrochlorothiazide in Hypertensive Patients

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion criteria:~* Essential hypertension.~* Currently taking between one and three antihypertensive medications at a stable dose for at least four weeks before Visit 1 of preceding trial 502.480.~* Blood pressure not adequately controlled on existing treatment before entry to preceding trial 502.480 (inadequate control defined as seated DBP \>= 95 mmHg on one current antihypertensive medication or DBP \>= 90 mmHg on two or more current antihypertensive medications).~* Failure to respond to six weeks run-in treatment with T80/H12.5 in preceding trial 502.480. (Failure to respond defined as seated DBP \>= 90 mmHg.)~* Willing and able to provide written informed consent.~Exclusion criteria:~* Women of child-bearing potential NOT practising acceptable means of birth control, positive serum pregnancy test, breastfeeding.~* Known or suspected secondary hypertension.~* Clinically significant change in ECG reported as adverse event in preceding trial 502.480.~* Any medical condition developing in preceding trial 502.480 that could be worsened by telmisartan/HCTZ (80/25).~* Discontinuation from preceding 502.480 trial for adverse event or any other reason.~* Mean SBP \>= 200 mmHg.~* Severe hepatic or renal impairment.~* Bilateral renal artery stenosis (or in a solitary kidney), post-renal transplant or only one functioning kidney.~* Clinically relevant hypokalaemia or hyperkalaemia.~* Uncorrected volume or sodium depletion, primary aldosteronism.~* Hereditary fructose intolerance.~* Previous symptoms of angioedema after ACE inhibitors or angiotensin-II receptor antagonists.~* Drug or alcohol dependency within the six months prior to entry to 502.480. concurrent participation in another clinical trial or any investigational therapy.~* Hypertrophic obstructive cardiomyopathy, hemodynamically relevant stenosis of the aortic or mitral valve.~* Allergic hypersensitivity to any component of the formulations under investigation.~* Concomitant therapy with lithium, cholestyramine or colestipol resins.~* Non-compliance with study medication (less than 80% or more than 120%) during the preceding 502.480 trial.~* Any other clinical condition which, in the opinion of the investigator, would not allow safe administration of telmisartan or hydrochlorothiazide.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).